$155 Million Pharma IPO Oversubscribed on Day 2: Rubicon Research Steals the Spotlight

Rubicon Research Ltd, a leading IP-driven pharmaceutical firm specializing in value-added formulations, achieved full subscription for its $155.3 million IPO on the second day of bidding, underscoring overwhelming investor appetite. The IPO opened on October 9, 2025, and is set to close on October 13, 2025.

The issue comprises a fresh equity share issuance worth $57 million alongside an offer-for-sale of $98 million by the promoter, General Atlantic Singapore RR Pte Ltd. Shares are priced in the band of approximately $5.9 to $6.2 per share (₹461-485), with a minimum application size set at 30 shares.

Retail individual investors showed strong enthusiasm, subscribing over twice their allocated quota, while non-institutional investors contributed healthy bids. Though Qualified Institutional Buyers subscribed moderately, overall demand ensured the issue’s full subscription on day 2, signaling confidence in Rubicon’s robust growth outlook and expanding portfolio.

Rubicon Research is focused on regulated markets, particularly the US, with diversified product offerings including oral solids, liquids, injectables, and drug-device combinations. The company reported a 48.5% revenue growth in FY 2025 with total income of approximately ₹1,296 crores (~$160 million) and improved EBITDA margins of 20.7%.

Proceeds from the IPO will primarily be deployed for debt repayment, inorganic growth through acquisitions, and corporate purposes. The company’s strong R&D base and acquisitions such as Validus Pharmaceuticals underpin its strategy to expand speciality pharma footprints and scale internationally.

Rubicon Research is expected to list on major Indian exchanges by October 16, 2025. Promoters’ holding will reduce post-IPO, with General Atlantic remaining a significant shareholder.

Important Points:

Rubicon Research’s $155.3 million IPO achieved full subscription by day 2, led by strong retail investor response.

The IPO comprises a fresh issue and promoter offer for sale totaling $155.3 million priced at $5.9-$6.2 per share.

Retail investors subscribed over 2x their quota; qualified institutional buyers subscribed moderately.

Funds will be primarily used for debt reduction, acquisitions, and corporate expansion initiatives.

Rubicon operates in speciality and generic pharma segments focused on global regulated markets, especially the US.

FY 2025 revenues surged 48.5% to ₹1,296 crore (~$160 million) with EBITDA margin above 20%.

Listing on BSE and NSE is slated for October 16, 2025, amid optimistic market sentiment driven by pharma sector growth potential.

Rubicon Research’s strong IPO subscription highlights growing investor confidence in its strategic growth trajectory, innovation pipeline, and global ambitions in speciality pharmaceuticals.

Sources: Groww; Economic Times; Moneycontrol; News18